ArticleFrontiers in pharmacology2023
Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- [Antimicrobial therapy of periprosthetic joint infection : Full version of the AE guidelines (2026)].Orthopadie (Heidelberg, Germany) · 2026Review
- Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study.Antibiotics (Basel, Switzerland) · 2026Article
- Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review.Infectious diseases and therapy · 2026Review
- Suppressive antibiotic therapy for spinal hardware infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil.Open forum infectious diseases · 2026Article
- Monthly dalbavancin dosing for suppressive therapy: a pharmacokinetic estimation analysis and case series.Antimicrobial agents and chemotherapy · 2026Article
- Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections.Antimicrobial agents and chemotherapy · 2025Observational
- Therapeutic Drug Monitoring Versus Fixed-Interval Dosing of Dalbavancin in Implant-Associated Spinal Infections: Grand Round/A Case Study.Therapeutic drug monitoring · 2025Article
- Dalbavancin as Suppressive Therapy for Implant-Associated Osteoarticular Infections.Antibiotics (Basel, Switzerland) · 2025Article
- Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review.Antibiotics (Basel, Switzerland) · 2025Review
- Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.Antimicrobial agents and chemotherapy · 2025Article
- Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Review
- New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.Pathogens (Basel, Switzerland) · 2024Review
- Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.Antibiotics (Basel, Switzerland) · 2023Article
- A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suppressive antibiotic therapy (SAT) is a strategy to alleviate symptoms and/or to reduce the progression of an infection when other treatment options cannot be used. Dalbavancin, due to its prolonged half-life, enables (bi) weekly dosing. Here, we report our multicenter real-life clinical experience with dalbavancin used as SAT in patients with prosthetic joint or vascular infections. Medical records of all adult patients with documented vascular or orthopedic chronic prosthetic infections, who received dalbavancin as SAT between 2016 and 2018 from four Spanish hospitals were reviewed for inclusion. Descriptive analysis of demographic characteristics, Charlson Comorbidity index, Barthel index, isolated pathogens and indication, concomitant antibiotic use, adverse events, and clinical outcome of SAT were performed. Eight patients were eligible for inclusion, where six patients had prosthetic vascular infections (aortic valve) and two patients had knee prosthetic joint infections. The most common pathogens were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.